Glück Conviction Score™ ⓘ
CYTK
CYTOKINETICS INC
Effektiv: Schwach
Hoch
Bedeutung der Einstufung ⓘ
Insider
0,0
Keine Insider-Käufe
Institutionell
48,6
78 neu, 188 erhöht, 488,7M $ netto
Aktivist
13,2
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,69% (Stand: 31.05.2026)
Score-Verlauf (90 Tage)
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (12 Monate)
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 70.12 | +0.0 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 63.00 | +11.3 % vs SMA200 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 71.61 | EMA50: 70.33 | |
| MACD-Histogramm | Bärisch | 10 % | -0.955 | Bearisch | |
| RSI(14) | Neutral | 10 % | 46.4 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 28.8 | Neutral | |
| ADX(14)+DI | Neutral | 10 % | 20.3 | +DI: 17.7 / −DI: 20.5 | |
| Z-Score(60) | Neutral | 5 % | 0.22 | In Range | |
| 52W-Position | Bullisch | 5 % | 81.4 % | Hoch 78.77 / Tief 32.43 | |
| Bollinger(20,2σ) | Neutral | 5 % | 27.0 % | Upper 80.82 / Mid 73.51 / Lower 66.19 | |
| LinReg-Slope(60) | Bullisch | 10 % | +0.2238 | R²=0.46 / annualisiert +81.8 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-06-09 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -3.500 | 67,98 | -237.930,00 | -54,3% | |
| 2026-06-01 | Kaye Edward M. MD | Director | Open Market Sale | -2.933 | 76,09 | -223.171,97 | -51,0% | |
| 2026-06-01 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -15.000 | 74,08 | -1.111.200,00 | -253,7% | |
| 2026-06-01 | PARSHALL B LYNNE | Director | Open Market Sale | -5.000 | 74,08 | -370.400,00 | -84,6% | |
| 2026-05-27 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -7.500 | 77,21 | -579.075,00 | -132,2% | |
| 2026-05-19 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -3.500 | 75,69 | -264.915,00 | -60,5% | |
| 2026-05-14 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -7.500 | 77,92 | -584.400,00 | -133,4% | |
| 2026-05-05 | WIERENGA WENDELL | Director | Open Market Sale | -4.032 | 75,00 | -302.400,00 | -69,1% | |
| 2026-05-05 | Lee Sung | Officer, EVP, Chief Financial Officer | Open Market Sale | -23.906 | 76,87 | -1.837.654,22 | -419,6% | |
| 2026-05-05 | HENDERSON JOHN T | Director | Open Market Sale | -20.000 | 75,97 | -1.519.400,00 | -347,0% | |
| 2026-05-05 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -3.500 | 77,37 | -270.795,00 | -61,8% | |
| 2026-05-05 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -11.333 | 77,25 | -875.474,25 | -199,9% | |
| 2026-05-01 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -15.857 | 65,00 | -1.030.705,00 | -235,4% | |
| 2026-04-30 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -15.000 | 63,26 | -948.900,00 | -216,7% | |
| 2026-04-29 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -7.500 | 59,62 | -447.150,00 | -102,1% | |
| 2026-04-21 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -3.500 | 65,69 | -229.915,00 | -52,5% | |
| 2026-04-15 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -7.449 | 66,02 | -491.782,98 | -112,3% | |
| 2026-04-15 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -7.500 | 65,38 | -490.350,00 | -112,0% | |
| 2026-04-07 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -1.000 | 64,75 | -64.750,00 | -14,8% | |
| 2026-04-07 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -3.500 | 65,21 | -228.235,00 | -52,1% | |
| 2026-04-01 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -7.500 | 66,63 | -499.725,00 | -114,1% | |
| 2026-03-31 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -3.639 | 65,00 | -236.535,00 | -54,0% | |
| 2026-03-18 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -1.930 | 62,07 | -119.795,10 | -27,4% | |
| 2026-03-17 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -4.397 | 62,15 | -273.273,55 | -62,4% | |
| 2026-03-17 | Lee Sung | Officer, EVP, Chief Financial Officer | Open Market Sale | -4.935 | 62,15 | -306.710,25 | -70,0% | |
| 2026-03-17 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -23.928 | 62,15 | -1.487.125,20 | -339,6% | |
| 2026-03-17 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -12.673 | 62,15 | -787.626,95 | -179,9% | |
| 2026-03-17 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -5.626 | 62,15 | -349.655,90 | -79,8% | |
| 2026-03-17 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -2.916 | 62,15 | -181.229,40 | -41,4% | |
| 2026-03-17 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -7.636 | 62,15 | -474.577,40 | -108,4% | |
| 2026-03-16 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -1.709 | 61,03 | -104.300,27 | -23,8% | |
| 2026-03-09 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2.907 | 60,72 | -176.513,04 | -40,3% | |
| 2026-03-09 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -2.582 | 60,72 | -156.779,04 | -35,8% | |
| 2026-03-09 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -7.931 | 60,72 | -481.570,32 | -110,0% | |
| 2026-03-05 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -15.000 | 61,87 | -928.050,00 | -211,9% | |
| 2026-03-05 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -11.000 | 61,88 | -680.680,00 | -155,4% | |
| 2026-03-02 | PARSHALL B LYNNE | Director | Open Market Sale | -5.000 | 61,21 | -306.050,00 | -69,9% | |
| 2026-03-02 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -886 | 61,62 | -54.595,32 | -12,5% | |
| 2026-02-05 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -15.000 | 61,93 | -928.950,00 | -212,1% | |
| 2026-02-02 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -886 | 62,10 | -55.020,60 | -12,6% | |
| 2026-01-05 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -15.000 | 60,28 | -904.200,00 | -206,5% | |
| 2026-01-02 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -913 | 62,09 | -56.688,17 | -12,9% | |
| 2026-01-02 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -885 | 63,16 | -55.896,60 | -12,8% | |
| 2025-12-29 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -1.809 | 62,44 | -112.953,96 | -25,8% | |
| 2025-12-22 | WIERENGA WENDELL | Director | Open Market Sale | -20.000 | 66,14 | -1.322.800,00 | -302,1% | |
| 2025-12-16 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2.200 | 61,24 | -134.728,00 | -30,8% | |
| 2025-12-08 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -1.042 | 65,96 | -68.730,32 | -15,7% | |
| 2025-12-05 | Callos Andrew | Officer, EVP, Chief Commercial Officer | Open Market Sale | -52.486 | 65,95 | -3.461.451,70 | -790,4% | |
| 2025-12-02 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2.200 | 63,89 | -140.558,00 | -32,1% | |
| 2025-12-02 | HENDERSON JOHN T | Director | Open Market Sale | -8.750 | 63,90 | -559.125,00 | -127,7% | |
| 2025-12-01 | Kaye Edward M. MD | Director | Open Market Sale | -28.064 | 66,72 | -1.872.430,08 | -427,6% | |
| 2025-12-01 | Harrington Robert Arthur | Director | Open Market Sale | -2.150 | 66,80 | -143.620,00 | -32,8% | |
| 2025-11-19 | PARSHALL B LYNNE | Director | Open Market Sale | -5.000 | 64,73 | -323.650,00 | -73,9% | |
| 2025-11-18 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2.200 | 66,45 | -146.190,00 | -33,4% | |
| 2025-11-11 | Kaye Edward M. MD | Director | Open Market Sale | -5.175 | 65,08 | -336.789,00 | -76,9% | |
| 2025-11-04 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2.295 | 59,55 | -136.667,25 | -31,2% | |
| 2025-10-30 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -5.000 | 62,86 | -314.300,00 | -71,8% | |
| 2025-10-27 | WIERENGA WENDELL | Director | Open Market Sale | -4.375 | 58,68 | -256.725,00 | -58,6% | |
| 2025-10-21 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2.105 | 58,22 | -122.553,10 | -28,0% | |
| 2025-10-16 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -5.000 | 60,03 | -300.150,00 | -68,5% | |
| 2025-10-07 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2.000 | 60,56 | -121.120,00 | -27,7% | |
| 2025-10-06 | Kaye Edward M. MD | Director | Open Market Sale | -6.757 | 60,00 | -405.420,00 | -92,6% | |
| 2025-10-01 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -5.000 | 55,05 | -275.250,00 | -62,9% | |
| 2025-09-30 | Kaye Edward M. MD | Director | Open Market Sale | -6.695 | 55,08 | -368.760,60 | -84,2% | |
| 2025-09-23 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2.000 | 49,28 | -98.560,00 | -22,5% | |
| 2025-09-15 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -5.000 | 49,77 | -248.850,00 | -56,8% | |
| 2025-09-09 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2.000 | 51,29 | -102.580,00 | -23,4% | |
| 2025-09-02 | Kaye Edward M. MD | Director | Open Market Sale | -6.756 | 50,00 | -337.800,00 | -77,1% | |
| 2025-09-02 | Harrington Robert Arthur | Director | Open Market Sale | -2.150 | 48,67 | -104.640,50 | -23,9% | |
| 2025-09-02 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -5.000 | 48,76 | -243.800,00 | -55,7% | |
| 2025-08-19 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2.000 | 38,31 | -76.620,00 | -17,5% | |
| 2025-08-15 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -5.000 | 38,42 | -192.100,00 | -43,9% | |
| 2025-08-05 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2.000 | 36,34 | -72.680,00 | -16,6% | |
| 2025-07-29 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -5.000 | 36,45 | -182.250,00 | -41,6% | |
| 2025-07-22 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2.000 | 37,47 | -74.940,00 | -17,1% | |
| 2025-07-14 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -5.000 | 38,15 | -190.750,00 | -43,6% | |
| 2025-07-08 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2.000 | 33,76 | -67.520,00 | -15,4% | |
| 2025-07-01 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -5.000 | 33,55 | -167.750,00 | -38,3% | |
| 2025-06-17 | Malik Fady Ibraham | Officer, EVP Research & Development | Open Market Sale | -2.000 | 32,91 | -65.820,00 | -15,0% | |
| 2025-06-16 | Blum Robert I | Director, Officer, President & CEO | Open Market Sale | -5.000 | 33,80 | -169.000,00 | -38,6% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 16.548.011 | 16.395.123 | 152.888 | 1.090.679.433 | Aufgestockt | +0,9% | |
| VANGUARD GROUP INC | 12.048.131 | 0 | 12.048.131 | 765.538.243 | Neu | +100,0% | |
| FMR LLC | 23.263.140 | 36.692.752 | -13.429.612 | 725.086.240 | Reduziert | -36,6% | |
| WELLINGTON MANAGEMENT GROUP LLP | 13.199.489 | 13.027.063 | 172.426 | 535.490.690 | Aufgestockt | +1,3% | |
| STATE STREET CORP | 5.745.193 | 5.825.295 | -80.102 | 378.665.671 | Reduziert | -1,4% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.488.634 | 0 | 5.488.634 | 361.755.867 | Neu | +100,0% | |
| Avoro Capital Advisors LLC | 3.333.333 | 0 | 3.333.333 | 219.699.978 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 8.283.436 | 22.380.152 | -14.096.716 | 213.534.616 | Reduziert | -63,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 3.215.415 | 3.056.017 | 159.398 | 211.965.492 | Aufgestockt | +5,2% | |
| RTW INVESTMENTS, LP | 2.721.158 | 2.721.158 | 0 | 179.351.524 | Unverändert | 0,0% | |
| ARMISTICE CAPITAL, LLC | 2.664.538 | 2.492.766 | 171.772 | 175.619.700 | Aufgestockt | +6,9% | |
| Integral Health Asset Management, LLC | 2.600.000 | 1.900.000 | 700.000 | 171.366.000 | Aufgestockt | +36,8% | |
| GOLDMAN SACHS GROUP INC | 4.265.758 | 6.503.079 | -2.237.321 | 164.503.872 | Reduziert | -34,4% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2.222.751 | 2.882.317 | -659.566 | 146.501.518 | Reduziert | -22,9% | |
| UBS Group AG | 2.102.177 | 1.131.456 | 970.721 | 138.554.486 | Aufgestockt | +85,8% | |
| BALYASNY ASSET MANAGEMENT L.P. | 36.742.145 | 36.002.500 | 739.645 | 124.443.571 | Aufgestockt | +2,1% | |
| Caption Management, LLC | 1.856.600 | 523.099 | 1.333.501 | 122.368.506 | Aufgestockt | +254,9% | |
| Polar Capital Holdings Plc | 1.661.248 | 2.455.612 | -794.364 | 109.492.856 | Reduziert | -32,3% | |
| MORGAN STANLEY | 4.666.075 | 5.220.301 | -554.226 | 103.818.602 | Reduziert | -10,6% | |
| CITADEL ADVISORS LLC | 1.554.358 | 1.573.637 | -19.279 | 102.447.736 | Reduziert | -1,2% | |
| Paradigm Biocapital Advisors LP | 1.480.857 | 0 | 1.480.857 | 97.603.285 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 1.441.634 | 1.380.787 | 60.847 | 95.018.097 | Aufgestockt | +4,4% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.397.045 | 1.383.437 | 13.608 | 92.079.236 | Aufgestockt | +1,0% | |
| JPMORGAN CHASE & CO | 2.651.697 | 0 | 2.651.697 | 91.774.036 | Neu | +100,0% | |
| Deep Track Capital, LP | 1.374.320 | 3.336.998 | -1.962.678 | 90.581.431 | Reduziert | -58,8% | |
| Capital International Investors | 1.338.803 | 1.178.780 | 160.023 | 88.240.506 | Aufgestockt | +13,6% | |
| LMR Partners LLP | 12.607.800 | 12.500.000 | 107.800 | 85.339.473 | Aufgestockt | +0,9% | |
| Ikarian Capital, LLC | 1.242.472 | 463.572 | 778.900 | 81.891.330 | Aufgestockt | +168,0% | |
| Frazier Life Sciences Management, L.P. | 1.159.879 | 934.642 | 225.237 | 76.447.625 | Aufgestockt | +24,1% | |
| PRINCIPAL FINANCIAL GROUP INC | 1.093.485 | 976.892 | 116.593 | 72.071.596 | Aufgestockt | +11,9% | |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 1.087.591 | 0 | 1.087.591 | 71.683.123 | Neu | +100,0% | |
| Woodline Partners LP | 1.000.428 | 1.648.428 | -648.000 | 65.938.209 | Reduziert | -39,3% | |
| Royalty Pharma Sub-Manager, LLC | 980.392 | 980.392 | 0 | 64.617.637 | Unverändert | 0,0% | |
| GROUP ONE TRADING LLC | 948.097 | 1.392.053 | -443.956 | 62.489.073 | Reduziert | -31,9% | |
| CAPSTONE INVESTMENT ADVISORS, LLC | 13.631.000 | 13.631.000 | 0 | 61.247.738 | Unverändert | 0,0% | |
| Logos Global Management LP | 875.000 | 300.000 | 575.000 | 57.671.250 | Aufgestockt | +191,7% | |
| BNP PARIBAS FINANCIAL MARKETS | 854.374 | 579.862 | 274.512 | 56.311.790 | Aufgestockt | +47,3% | |
| Melqart Asset Management (UK) Ltd | 843.949 | 622.898 | 221.051 | 55.624.679 | Aufgestockt | +35,5% | |
| Qube Research & Technologies Ltd | 779.446 | 537.277 | 242.169 | 51.373.286 | Aufgestockt | +45,1% | |
| NORGES BANK | 807.070 | 0 | 807.070 | 51.281.228 | Neu | +100,0% | |
| Capital Research Global Investors | 770.999 | 0 | 770.999 | 50.816.544 | Neu | +100,0% | |
| BNP Paribas Asset Management Holding S.A. | 3.214.344 | 3.977.863 | -763.519 | 50.778.273 | Reduziert | -19,2% | |
| Fisher Asset Management, LLC | 768.264 | 822.885 | -54.621 | 50.636.280 | Reduziert | -6,6% | |
| Pictet Asset Management Holding SA | 750.953 | 757.563 | -6.610 | 49.297.191 | Reduziert | -0,9% | |
| D. E. Shaw & Co., Inc. | 747.331 | 200.721 | 546.610 | 49.256.586 | Aufgestockt | +272,3% | |
| Affinity Asset Advisors, LLC | 700.483 | 800.000 | -99.517 | 46.168.835 | Reduziert | -12,4% | |
| FEDERATED HERMES, INC. | 699.453 | 483.668 | 215.785 | 46.100.947 | Aufgestockt | +44,6% | |
| Nuveen, LLC | 14.351.809 | 5.369.279 | 8.982.530 | 43.645.232 | Aufgestockt | +167,3% | |
| Point72 Asset Management, L.P. | 661.002 | 37.200 | 623.802 | 43.566.642 | Aufgestockt | +1676,9% | |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. | 660.310 | 747.983 | -87.673 | 43.521.032 | Reduziert | -11,7% |
Top-Fondshalter (Stand: 31.03.2026) ⓘ
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) |
|---|---|---|---|---|---|
| BlackRock, Inc. | 16.548.011 | 16.395.123 | +0,9% | 1.090.679.433 | 12,38 |
| FMR LLC | 23.263.140 | 36.692.752 | -36,6% | 725.086.240 | 8,23 |
| WELLINGTON MANAGEMENT GROUP LLP | 13.199.489 | 13.027.063 | +1,3% | 535.490.690 | 6,08 |
| STATE STREET CORP | 5.745.193 | 5.825.295 | -1,4% | 378.665.671 | 4,30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.488.634 | 0 | +100,0% | 361.755.867 | 4,11 |
| Avoro Capital Advisors LLC | 3.333.333 | 0 | +100,0% | 219.699.978 | 2,49 |
| BANK OF AMERICA CORP /DE/ | 8.283.436 | 22.380.152 | -63,0% | 213.534.616 | 2,42 |
| GEODE CAPITAL MANAGEMENT, LLC | 3.215.415 | 3.056.017 | +5,2% | 211.965.492 | 2,41 |
| RTW INVESTMENTS, LP | 2.721.158 | 2.721.158 | 0,0% | 179.351.524 | 2,04 |
| ARMISTICE CAPITAL, LLC | 2.664.538 | 2.492.766 | +6,9% | 175.619.700 | 1,99 |
| Integral Health Asset Management, LLC | 2.600.000 | 1.900.000 | +36,8% | 171.366.000 | 1,95 |
| GOLDMAN SACHS GROUP INC | 4.265.758 | 6.503.079 | -34,4% | 164.503.872 | 1,87 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2.222.751 | 2.882.317 | -22,9% | 146.501.518 | 1,66 |
| UBS Group AG | 2.102.177 | 1.131.456 | +85,8% | 138.554.486 | 1,57 |
| BALYASNY ASSET MANAGEMENT L.P. | 36.742.145 | 36.002.500 | +2,1% | 124.443.571 | 1,41 |
| Caption Management, LLC | 1.856.600 | 523.099 | +254,9% | 122.368.506 | 1,39 |
| Polar Capital Holdings Plc | 1.661.248 | 2.455.612 | -32,3% | 109.492.856 | 1,24 |
| MORGAN STANLEY | 4.666.075 | 5.220.301 | -10,6% | 103.818.602 | 1,18 |
| CITADEL ADVISORS LLC | 1.554.358 | 1.573.637 | -1,2% | 102.447.736 | 1,16 |
| Paradigm Biocapital Advisors LP | 1.480.857 | 0 | +100,0% | 97.603.285 | 1,11 |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 31.03.2026 | ✓ | 453 | 305,6 | 9.736 |
| 31.12.2025 | ✓ | 440 | 328,4 | 9.016 |
| 30.09.2025 | ✓ | 397 | 344,9 | 7.582 |
| 30.06.2025 | ✓ | 333 | 684,4 | 4.727 |
| 31.03.2025 | ✓ | 370 | 692,8 | 6.189 |
| 31.12.2024 | ✓ | 362 | 652,9 | 6.521 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) ⓘ |
|---|---|---|
| Royalty Pharma Sub-Manager, LLC | 980.392 | 62.294.108 |
| NORGES BANK | 807.070 | 51.281.228 |
| TWO SIGMA INVESTMENTS, LP | 8.774.017 | 29.502.290 |
| ExodusPoint Capital Management, LP | 343.144 | 21.803.370 |
| GSK plc | 340.434 | 21.631.176 |
| Logos Global Management LP | 300.000 | 19.062.000 |
| TWO SIGMA ADVISERS, LP | 174.700 | 11.100.438 |
| STEMPOINT CAPITAL LP | 146.978 | 9.338.982 |
| Candriam S.C.A. | 146.631 | 9.317.330 |
| Hood River Capital Management LLC | 137.597 | 8.742.913 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| BALYASNY ASSET MANAGEMENT L.P. | 36.002.500 | 11.747.900 | +48.4 % | 73.460.759 |
| Nuveen, LLC | 5.369.279 | 4.998.364 | +1347.6 % | 30.576.487 |
| Jefferies Financial Group Inc. | 4.270.000 | 1.818.000 | +74.1 % | 9.230.742 |
| BNP Paribas Asset Management Holding S.A. | 3.977.863 | 1.692.863 | +74.1 % | 57.068 |
| Context Capital Management, LLC | 1.386.000 | 1.384.614 | +99900.0 % | 1.975.743 |
| BlackRock, Inc. | 16.395.123 | 869.376 | +5.6 % | 1.041.746.107 |
| GROUPAMA ASSET MANAGMENT | 1.150.000 | 800.000 | +228.6 % | 1.621.282 |
| Qube Research & Technologies Ltd | 537.277 | 528.239 | +5844.6 % | 34.138.581 |
| JANE STREET GROUP, LLC | 1.603.125 | 468.425 | +41.3 % | 75.462.518 |
| FEDERATED HERMES, INC. | 483.668 | 457.874 | +1775.1 % | 30.732.264 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | 13.027.063 | -9.571.498 | -42.4 % | 511.603.369 |
| FMR LLC | 36.692.752 | -7.423.895 | -16.8 % | 847.780.995 |
| CITIGROUP INC | 289.501 | -2.554.897 | -89.8 % | 18.394.893 |
| WELLS FARGO & COMPANY/MN | 161.556 | -1.910.004 | -92.2 % | 10.265.298 |
| BANK OF AMERICA CORP /DE/ | 22.380.152 | -1.447.644 | -6.1 % | 214.532.776 |
| T. Rowe Price Investment Management, Inc. | 17.716.372 | -1.364.124 | -7.1 % | 1.125.699 |
| GABELLI FUNDS LLC | 14.209 | -1.020.550 | -98.6 % | 902.840 |
| Deep Track Capital, LP | 3.336.998 | -963.002 | -22.4 % | 212.032.853 |
| UBS Group AG | 1.131.456 | -691.595 | -37.9 % | 71.892.714 |
| GOLDMAN SACHS GROUP INC | 6.503.079 | -486.644 | -7.0 % | 170.326.215 |
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck |
|---|---|---|---|---|---|---|
| 06.05.2026 | FMR LLC | Passiv (13G/A) | 9,00 % | 11.135.192 | -1,90 pp | |
| 06.05.2026 | Abigail P. Johnson | Passiv (13G/A) | 9,00 % | 11.135.192 | -1,90 pp | |
| 30.04.2026 | Vanguard Capital Management | Passiv (13G) | 5,21 % | 6.422.042 | Neu | |
| 26.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -10,09 pp | |
| 17.02.2026 | T. Rowe Price Investment Management, Inc. | Passiv (13G/A) | 14,50 % | 17.716.372 | -1,50 pp | |
| 14.11.2025 | T. Rowe Price Investment Management, Inc. | Passiv (13G/A) | 16,00 % | 19.097.373 | +1,30 pp | |
| 10.11.2025 | STATE STREET CORPORATION | Passiv (13G) | 4,70 % | 5.617.334 | Neu | |
| 14.08.2025 | T. Rowe Price Investment Management, Inc. | Passiv (13G/A) | 14,70 % | 17.602.440 | +3,40 pp | |
| 07.08.2025 | FMR LLC | Passiv (13G/A) | 10,90 % | 13.101.596 | +1,50 pp | |
| 07.08.2025 | Abigail P. Johnson | Passiv (13G/A) | 10,90 % | 13.101.596 | +1,50 pp | |
| 07.05.2025 | T. Rowe Price Investment Management, Inc. | Passiv (13G) | 11,30 % | 13.420.144 | +3,10 pp | |
| 12.02.2025 | Abigail P. Johnson | Passiv (13G/A) | 9,40 % | 11.146.954 | Neu | |
| 12.02.2025 | FMR LLC | Passiv (13G/A) | 9,40 % | 11.146.954 | Neu | |
| 08.01.2025 | The Vanguard Group | Passiv (13G/A) | 10,09 % | 11.915.821 | +0,10 pp | |
| 14.11.2024 | T. Rowe Price Investment Management, Inc. | Passiv (13G) | 8,20 % | 9.689.987 | Neu | |
| 12.11.2024 | . BlackRock, Inc. | Passiv (13G/A) | 13,00 % | 15.252.905 | 0,00 pp | |
| 12.11.2024 | The Vanguard Group | Passiv (13G/A) | 9,99 % | 11.761.605 | 0,00 pp | |
| 04.11.2024 | The Vanguard Group | Passiv (13G/A) | 9,99 % | 11.761.605 | -1,25 pp | |
| 23.10.2024 | . BlackRock, Inc. | Passiv (13G/A) | 13,00 % | 15.252.905 | -3,40 pp | |
| 13.02.2024 | The Vanguard Group | Passiv (13G/A) | 11,24 % | 11.016.889 | +0,60 pp | |
| 08.02.2024 | Wellington Management Group LLP | Passiv (13G/A) | 6,66 % | 6.530.884 | -0,25 pp | |
| 08.02.2024 | Wellington Group Holdings LLP | Passiv (13G/A) | 6,66 % | 6.530.884 | -0,25 pp | |
| 08.02.2024 | Wellington Investment Advisors Holdings LLP | Passiv (13G/A) | 6,66 % | 6.530.884 | -0,25 pp | |
| 08.02.2024 | Wellington Management Company LLP | Passiv (13G/A) | 6,45 % | 6.325.032 | -0,22 pp | |
| 25.01.2024 | : STATE STREET CORPORATION | Passiv (13G/A) | 6,01 % | 0 | +0,68 pp | |
| 22.01.2024 | . BlackRock, Inc. | Passiv (13G/A) | 16,40 % | 16.102.070 | -0,30 pp | |
| 10.02.2023 | . BlackRock, Inc. | Passiv (13G/A) | 16,70 % | 15.767.874 | +0,70 pp | |
| 09.02.2023 | The Vanguard Group | Passiv (13G/A) | 10,64 % | 10.073.094 | +0,34 pp | |
| 06.02.2023 | Wellington Management Company LLP | Passiv (13G) | 6,67 % | 6.312.435 | Neu | |
| 06.02.2023 | Wellington Group Holdings LLP | Passiv (13G) | 6,91 % | 6.542.724 | Neu | |
| 06.02.2023 | Wellington Investment Advisors Holdings LLP | Passiv (13G) | 6,91 % | 6.542.724 | Neu | |
| 06.02.2023 | Wellington Management Group LLP | Passiv (13G) | 6,91 % | 6.542.724 | Neu | |
| 03.02.2023 | : STATE STREET CORPORATION | Passiv (13G/A) | 5,33 % | 0 | +0,58 pp | |
| 26.01.2023 | . BlackRock, Inc. | Passiv (13G/A) | 16,00 % | 14.967.317 | 0,00 pp | |
| 20.01.2023 | . BlackRock, Inc. | Passiv (13G/A) | 16,00 % | 14.967.317 | +0,60 pp | |
| 08.04.2022 | The Vanguard Group | Passiv (13G/A) | 10,30 % | 8.741.124 | +1,97 pp | |
| 14.02.2022 | DRIEHAUS CAPITAL MANAGEMENT LLC | Passiv (13G/A) | 2,77 % | 2.327.112 | +2,77 pp | |
| 09.02.2022 | The Vanguard Group | Passiv (13G/A) | 8,33 % | 6.989.719 | +1,52 pp | |
| 09.02.2022 | : STATE STREET CORPORATION | Passiv (13G/A) | 4,75 % | 0 | -1,81 pp | |
| 27.01.2022 | . BlackRock, Inc. | Passiv (13G/A) | 15,40 % | 12.950.964 | 0,00 pp |
US Congress Trades (STOCK Act)
| Datum | Mitglied | Partei | Kammer | Typ | Betrag-Bereich |
|---|---|---|---|---|---|
| 09.10.2025 | Gilbert Cisneros | – | House | Kauf | $1,001 – $15,000 |
| 17.06.2025 | Lisa McClain | – | House | Verkauf | $1,001 – $15,000 |
| 11.06.2025 | Lisa McClain | – | House | Kauf | $1,001 – $15,000 |
Quelle: House eFD & Senate eFD (STOCK Act PTR). Betragsangaben sind Bereichsangaben — keine Exaktwerte. Tiefenanalyse für diese Aktie → · Alle Kongress-Bestände →
Stammdaten
Cytokinetics, Incorporated, ein fortgeschrittenes biopharmazeutisches Unternehmen, konzentriert sich auf die Entdeckung, Entwicklung und Vermarktung von Muskelaktivatoren und -inhibitoren als potenzielle Behandlungen für schwächende Krankheiten. Das Unternehmen entwickelt hauptsächlich kleine Moleküle-Wirkstoffkandidaten, die auf die Beeinflussung der Muskelfunktion und Kontraktilität ausgerichtet sind. Die Wirkstoffkandidaten umfassen Omecamtiv Mecarbil, einen neuartigen kardialen Myosin-Aktivator, der sich in Phase III Klinikversuchen bei Patienten mit Herzinsuffizienz befindet; und Reldesemtiv, einen Skelettmuskel-Troponin-Aktivator, der sich in Phase III Klinikversuchen zur Behandlung von amyotropher Lateralsklerose und spinaler Muskelatrophie befindet. Das Unternehmen entwickelt auch CK-136, einen neuartigen kardialen Troponin-Aktivator, der sich in Phase I Klinikversuchen befindet; Aficamten, einen neuartigen kardialen Myosin-Inhibitor, der sich in Phase III Klinikversuchen zur Behandlung von Patienten mit symptomatischer obstruktiver hypertrophischer Kardiomyopathie befindet; und CK-3772271, einen kleinen Moleküle-Inhibitor für kardiales Myosin, der sich in Phase I Klinikversuchen befindet. Cytokinetics, Incorporated hat eine strategische Allianz mit Astellas Pharma Inc. Das Unternehmen wurde 1997 gegründet und hat seinen Hauptsitz in South San Francisco, Kalifornien.
Unternehmen & Branche
| Name | CYTOKINETICS INC |
|---|---|
| Ticker | CYTK |
| CIK | 0001061983 |
| Boerse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 23282W605 |
|---|---|
| ISIN | US23282W6057 |
| Typ | Common Stock |
| Marktkapitalisierung | 8,25 Mrd. USD |
| Beta | 0,35 |
Bewertung
| KUV (P/S) | 93,66 vs. 54,88 (2021) ▲ |
|---|---|
| FCF-Rendite | -6,5 % vs. -5,0 % (2021) ▼ |
Qualität & Bilanz
| Operative Marge | -695,4 % vs. -264,5 % (2021) ▼ |
|---|---|
| Nettomarge | -891,6 % vs. -305,7 % (2021) ▼ |
| Zinsdeckungsgrad | -13,4 vs. -11,3 (2021) ▼ |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | Verlauf |
|---|---|---|---|---|---|---|
| Bewertung | ||||||
| KUV (P/S) | 54,88 | 45,94 | 1.126,93 | 300,99 | 88,73 | |
| FCF-Rendite | -5,0 % | -7,2 % | -4,9 % | -7,2 % | -6,8 % | |
| Qualität & Bilanz | ||||||
| Operative Marge | -264,5 % | -342,8 % | -6.589,7 % | -2.902,7 % | -695,4 % | |
| Nettomarge | -305,7 % | -411,2 % | -6.988,6 % | -3.191,1 % | -891,6 % | |
| ROIC | -51,5 % | -402,7 % | – | -584,1 % | – | |
| Zinsdeckungsgrad | -11,3 | -16,7 | -17,5 | -14,2 | -13,4 | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Finanzkennzahlen (SEC XBRL) ⓘ
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | 19.355.000 | -206.031.000 | -1,67 | 1.273.478.000 | -826.568.000 |
| 2025-12-31 | 10-K | 88.039.000 | -784.955.000 | -6,54 | 1.424.537.000 | -659.625.000 |
| 2025-09-30 | 10-Q | 1.936.000 | -306.178.000 | -2,55 | 1.436.557.000 | -521.123.000 |
| 2025-06-30 | 10-Q | 66.769.000 | -134.370.000 | -1,12 | 1.225.635.000 | -368.720.000 |
| 2025-03-31 | 10-Q | 1.579.000 | -161.376.000 | -1,36 | 1.264.051.000 | -266.413.000 |
| 2024-12-31 | 10-Q | 15.000.000 | 1.401.673.000 | -135.372.000 | ||
| 2024-12-31 | 10-K | 18.474.000 | -589.526.000 | -5,26 | 1.401.673.000 | -135.372.000 |
| 2024-09-30 | 10-Q | 463.000 | -160.545.000 | -1,36 | 1.436.060.000 | -13.911.000 |
| 2024-06-30 | 10-Q | 249.000 | -143.318.000 | -1,31 | 1.523.788.000 | 108.550.000 |
| 2024-03-31 | 10-Q | 835.000 | -135.643.000 | -1,33 | 808.082.000 | -396.160.000 |
| 2023-12-31 | 10-K | 7.530.000 | -526.244.000 | -5,45 | 824.316.000 | -386.323.000 |
| 2023-09-30 | 10-Q | 378.000 | -129.422.000 | -1,35 | 740.614.000 | -438.801.000 |
| 2023-06-30 | 10-Q | 867.000 | -128.637.000 | -1,34 | 779.899.000 | -333.115.000 |
| 2023-03-31 | 10-Q | 4.613.000 | -131.289.000 | -1,38 | 889.815.000 | -229.020.000 |
| 2022-12-31 | 10-K | 94.588.000 | -388.955.000 | -4,33 | 1.014.775.000 | -107.900.000 |
| 2022-09-30 | 10-Q | 2.515.000 | -142.310.000 | -1,52 | 1.075.961.000 | -15.977.000 |
| 2022-06-30 | 10-Q | 88.968.000 | -19.820.000 | -0,23 | 771.717.000 | 111.414.000 |
| 2022-03-31 | 10-Q | 1.148.000 | -89.445.000 | -1,05 | 856.253.000 | 116.261.000 |
| 2021-12-31 | 10-K | 70.428.000 | -215.314.000 | -2,80 | 841.319.000 | 243.863.000 |
| 2021-09-30 | 10-Q | 5.437.000 | -76.086.000 | -0,95 | 827.539.000 | 249.020.000 |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| License And Milestone Revenues | 79,4 Mio. | 15,0 Mio. | 3,5 Mio. | 1,0 Mio. | 54,9 Mio. | 90,1 % | +429,0% | |
| Collaboration Revenues | 8,7 Mio. | 3,5 Mio. | 4,0 Mio. | 6,6 Mio. | – | 9,9 % | +150,0% | |
| Realization Of Revenue Participation Right Purchase Agreement | – | – | – | 87,0 Mio. | – | – | – |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 05.05.2026 | 19,4 Mio. USD | -1,67 |
| Q3 2025 | 30.09.2025 | 05.11.2025 | 1,9 Mio. USD | -2,55 |
| Q2 2025 | 30.06.2025 | 05.11.2025 | 66,8 Mio. USD | -1,12 |
| Q1 2025 | 31.03.2025 | 05.05.2026 | 1,6 Mio. USD | -1,36 |
| Q3 2024 | 30.09.2024 | 05.11.2025 | 463.000 USD | -1,36 |
| Q2 2024 | 30.06.2024 | 05.11.2025 | 249.000 USD | -1,31 |
| Q1 2024 | 31.03.2024 | 05.11.2025 | 835.000 USD | -1,33 |
| Q3 2023 | 30.09.2023 | 07.11.2024 | 378.000 USD | -1,35 |
| Q2 2023 | 30.06.2023 | 07.11.2024 | 867.000 USD | -1,34 |
Einreichungs-Historie (10-K / 10-Q)
SEC-Einreichungs-Historie der Quartalsberichte (10-Q) und Jahresberichte
(10-K) der letzten sechs Jahre. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 05.05.2026 | 10-Q | 31.03.2026 | 35 Tage | SEC » |
| 26.02.2026 | 10-K | 31.12.2025 | 57 Tage | SEC » |
| 05.11.2025 | 10-Q | 30.09.2025 | 36 Tage | SEC » |
| 07.08.2025 | 10-Q | 30.06.2025 | 38 Tage | SEC » |
| 06.05.2025 | 10-Q | 31.03.2025 | 36 Tage | SEC » |
| 27.02.2025 | 10-K | 31.12.2024 | 58 Tage | SEC » |
| 07.11.2024 | 10-Q | 30.09.2024 | 38 Tage | SEC » |
| 09.08.2024 | 10-Q | 30.06.2024 | 40 Tage | SEC » |
| 10.05.2024 | 10-Q | 31.03.2024 | 40 Tage | SEC » |
| 28.02.2024 | 10-K | 31.12.2023 | 59 Tage | SEC » |
| 03.11.2023 | 10-Q | 30.09.2023 | 34 Tage | SEC » |
| 03.08.2023 | 10-Q | 30.06.2023 | 34 Tage | SEC » |
| 05.05.2023 | 10-Q | 31.03.2023 | 35 Tage | SEC » |
| 01.03.2023 | 10-K | 31.12.2022 | 60 Tage | SEC » |
| 04.11.2022 | 10-Q | 30.09.2022 | 35 Tage | SEC » |
| 05.08.2022 | 10-Q | 30.06.2022 | 36 Tage | SEC » |
| 06.05.2022 | 10-Q | 31.03.2022 | 36 Tage | SEC » |
| 25.02.2022 | 10-K | 31.12.2021 | 56 Tage | SEC » |
| 05.11.2021 | 10-Q | 30.09.2021 | 36 Tage | SEC » |
| 06.08.2021 | 10-Q | 30.06.2021 | 37 Tage | SEC » |
| 07.05.2021 | 10-Q | 31.03.2021 | 37 Tage | SEC » |
| 11.03.2021 | 10-Q/A | 30.09.2020 | 162 Tage | SEC » |
| 26.02.2021 | 10-K | 31.12.2020 | 57 Tage | SEC » |
| 06.11.2020 | 10-Q | 30.09.2020 | 37 Tage | SEC » |
| 07.08.2020 | 10-Q | 30.06.2020 | 38 Tage | SEC » |
Kritische 8-K Meldungen ⓘ
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 14.11.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 20.08.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 11.02.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 16.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 07.11.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 15.08.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 17.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 3(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 26.04.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 3(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 02.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment… |
| 24.02.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors… |
| 27.05.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 08.04.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 01.03.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 24.02.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 19.02.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-05-14 | 45 | 77,22 | 3.475 |
| 2026-05-13 | 27.719 | 74,81 | 2.073.658 |
| 2026-05-11 | 4 | 76,91 | 308 |
| 2026-05-08 | 2.437.516 | 74,29 | 181.083.064 |
| 2026-05-07 | 874 | 74,84 | 65.410 |
| 2026-05-06 | 274.693 | 77,09 | 21.176.083 |
| 2026-05-05 | 7.318 | 66,05 | 483.354 |
| 2026-05-01 | 4.607 | 63,97 | 294.710 |
| 2026-04-30 | 6.902 | 59,58 | 411.221 |
| 2026-04-28 | 10.929 | 61,60 | 673.226 |
| 2026-04-23 | 75 | 66,25 | 4.969 |
| 2026-04-22 | 822 | 65,80 | 54.088 |
| 2026-04-15 | 1.020 | 66,35 | 67.677 |
| 2026-04-14 | 1 | 66,72 | 67 |
| 2026-04-10 | 746 | 64,59 | 48.184 |
| 2026-04-08 | 12.406 | 65,48 | 812.345 |
| 2026-04-06 | 95.167 | 66,73 | 6.350.494 |
| 2026-04-01 | 4 | 65,91 | 264 |
| 2026-03-31 | 419 | 62,97 | 26.384 |
| 2026-03-30 | 69 | 62,50 | 4.313 |
| 2026-03-27 | 668 | 63,48 | 42.405 |
| 2026-03-26 | 369 | 62,39 | 23.022 |
| 2026-03-25 | 25.106 | 60,02 | 1.506.862 |
| 2026-03-24 | 2 | 60,95 | 122 |
| 2026-03-23 | 1.619 | 61,70 | 99.892 |
| 2026-03-20 | 400 | 62,95 | 25.180 |
| 2026-03-18 | 27 | 62,13 | 1.678 |
| 2026-03-10 | 242 | 62,42 | 15.106 |
| 2026-03-06 | 521 | 62,19 | 32.401 |
| 2026-02-27 | 55.565 | 62,63 | 3.480.036 |
| 2026-02-26 | 4.625 | 62,89 | 290.866 |
| 2026-02-24 | 82.065 | 68,26 | 5.601.757 |
| 2026-02-20 | 2 | 67,83 | 136 |
| 2026-02-19 | 4.620 | 66,98 | 309.448 |
| 2026-02-17 | 3.573 | 66,26 | 236.747 |
| 2026-02-13 | 5.694 | 65,04 | 370.338 |
| 2026-02-12 | 320 | 66,80 | 21.376 |
| 2026-02-11 | 78 | 64,85 | 5.058 |
| 2026-02-03 | 10 | 65,16 | 652 |
| 2026-01-30 | 96 | 65,60 | 6.298 |
| 2026-01-29 | 434 | 65,14 | 28.271 |
| 2026-01-27 | 14 | 63,19 | 885 |
| 2026-01-23 | 11.520 | 64,93 | 747.994 |
| 2026-01-13 | 110 | 64,64 | 7.110 |
| 2026-01-07 | 7.783 | 64,60 | 502.782 |
| 2026-01-06 | 1 | 61,26 | 61 |
| 2025-12-26 | 3.685 | 64,18 | 236.503 |
| 2025-12-23 | 2 | 65,60 | 131 |
| 2025-12-22 | 20.156 | 62,69 | 1.263.580 |
| 2025-12-17 | 15.000 | 62,02 | 930.300 |